In the closing days of September, a European regulatory body moved to widen the circle of care for millions living with chronic inflammatory disease — recommending approval of Gobivaz, a biosimilar to the biologic golimumab, developed by Iceland's Alvotech and set to be commercialized across Europe by Advanz Pharma. The decision, still awaiting formal confirmation from the European Commission, reflects a quiet but consequential shift in modern medicine: as patents on complex biologic therapies expire, their more affordable counterparts are becoming instruments of both economic relief and expan
The Manila Times
· Sep 22, 2025
· health
· 9 min read
High
Sourcing: Verified
EMA Recommends Approval of Gobivaz, Alvotech's Golimumab Biosimilar
Potential positive impact: biosimilar approval could improve patient access to affordable treatment for chronic inflammatory diseases affecting millions in Europe.
◉
Health & Medicine
8046 related articles
Blood test could predict Covid-19 mortality risk, study finds
BreakingNews.ie · 100% match
Hadassah performs world's first alpha radiation treatment for recurren…
jpost.com · 99% match
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 99% match
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% match
Canada faces new COVID epidemic, not third wave, as variants target di…
The Globe and Mail · 99% match
Related Coverage
Google News · Aug 19
Welsh Teen's Ovarian Cancer Diagnosis Triggers Sudden Menopause
A teenager from Caernarfon experienced sudden onset menopause following an ovarian cancer diagnosis, highlighting unexpe…
JNS.org · Aug 19 Israeli study: Focused attention may reduce inflammatory responseBar-Ilan University researchers found that deliberately focusing attention on inflamed skin areas reduced inflammatory r…
foodsafetynews.com · Aug 19 UK Salmonella outbreak sickens 207, linked to imported eggsA Salmonella outbreak across the UK has infected 207 people with one death, traced to contaminated imported eggs served …
eNCA · Aug 19 DRC Ebola outbreak spreading faster than any previous epidemic, WHO warnsWHO warns the DRC Ebola outbreak is moving faster than any previous epidemic, with over 2,300 deaths from nearly 5,000 c…
Bias & Framing
⚖
Press release presents EMA approval recommendation for biosimilar with minimal critical analysis, using corporate language and positive framing without addressing cost, efficacy comparisons, or market implications.
Bias Direction
center-right
Confidence
HIGH
Corporate announcement framing presented as news; uses optimistic language around 'access' and 'milestones' without independent verification or critical context; structured to amplify company messaging.
increase access for patients
important milestone
significant step forward
leading biosimilars presence
positive opinion
important treatment option
Independent medical/scientific analysis of biosimilar efficacy vs. reference drug
Patient advocacy group perspectives on pricing and actual accessibility
Competitive landscape and market impact on existing treatments
Potential concerns or limitations from regulatory bodies
Healthcare cost implications for EU systems
Timeline and likelihood of final European Commission approval
Comparison to other golimumab biosimilars in development
Geopolitical Impact
🌎
EMA approval of Icelandic biosimilar expands European pharmaceutical competition, reducing drug costs but shifting market dynamics away from US-based innovators in inflammatory disease treatment.
Escalation Risk
low
Confidence
HIGH
European Union
Iceland
Norway
Liechtenstein
United Kingdom
United States
Biosimilar approval strengthens European pharmaceutical sovereignty and reduces dependence on US biologics pricing. Alvotech (Iceland) and Advanz Pharma (UK) gain market share from Johnson & Johnson's Simponi®, reflecting broader shift toward cost-containment in EU healthcare systems and emerging biotech competition from non-traditional pharma hubs.
Similar to generic drug revolutions in the 1980s-90s, biosimilar approvals represent democratization of expensive biologics, reducing US pharma monopolies and enabling emerging biotech nations to compete globally.
Economic Lens
📈
EMA recommends approval of Gobivaz, a golimumab biosimilar, expanding affordable treatment options for chronic inflammatory diseases across EU/EEA, potentially reducing healthcare costs and increasing market competition.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical Manufacturing
Biotechnology
Healthcare Services
Medical Devices
Healthcare Insurance
Patients gain access to more affordable biosimilar alternatives for treating rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and juvenile idiopathic arthritis, potentially reducing out-of-pocket costs and improving treatment accessibility across EU/EEA nations.
Regulatory approval strengthens EU biosimilar market competition, supporting healthcare cost containment policies. May encourage similar approvals for other biosimilars, incentivizing generic/biosimilar development and potentially prompting reference biologic manufacturers to adjust pricing strategies.